PMC:7033706 / 6794-7331 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"183","span":{"begin":229,"end":230},"obj":"Gene"},{"id":"184","span":{"begin":23,"end":31},"obj":"Species"},{"id":"185","span":{"begin":36,"end":44},"obj":"Species"},{"id":"186","span":{"begin":219,"end":228},"obj":"Species"},{"id":"187","span":{"begin":284,"end":293},"obj":"Species"},{"id":"188","span":{"begin":386,"end":394},"obj":"Species"},{"id":"189","span":{"begin":402,"end":410},"obj":"Species"}],"attributes":[{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"Gene:43740568"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"Tax:694009"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"Tax:1335626"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"Tax:2697049"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"Tax:2697049"},{"id":"A188","pred":"tao:has_database_id","subj":"188","obj":"Tax:694009"},{"id":"A189","pred":"tao:has_database_id","subj":"189","obj":"Tax:1335626"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The recently developed SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are specific to the S1 subunit of S protein, particularly the RBD [5,89–10]. Therefore, the 2019-nCoV S-RBD is anticipated to be a key target for developing 2019-nCoV neutralizing mAbs. The neutralizing mAbs targeting non-RBD regions, including NTD and S2 of SARS-CoV and/or MERS-CoV S could also be identified [5,8,11,12], although their neutralizing potency is generally lower than that of RBD-specific mAbs."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T22","span":{"begin":163,"end":170},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"The recently developed SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are specific to the S1 subunit of S protein, particularly the RBD [5,89–10]. Therefore, the 2019-nCoV S-RBD is anticipated to be a key target for developing 2019-nCoV neutralizing mAbs. The neutralizing mAbs targeting non-RBD regions, including NTD and S2 of SARS-CoV and/or MERS-CoV S could also be identified [5,8,11,12], although their neutralizing potency is generally lower than that of RBD-specific mAbs."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T30","span":{"begin":23,"end":31},"obj":"Disease"},{"id":"T31","span":{"begin":372,"end":375},"obj":"Disease"},{"id":"T33","span":{"begin":386,"end":394},"obj":"Disease"}],"attributes":[{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0008449"},{"id":"A32","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0018075"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The recently developed SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are specific to the S1 subunit of S protein, particularly the RBD [5,89–10]. Therefore, the 2019-nCoV S-RBD is anticipated to be a key target for developing 2019-nCoV neutralizing mAbs. The neutralizing mAbs targeting non-RBD regions, including NTD and S2 of SARS-CoV and/or MERS-CoV S could also be identified [5,8,11,12], although their neutralizing potency is generally lower than that of RBD-specific mAbs."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T91","span":{"begin":147,"end":149},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T92","span":{"begin":256,"end":257},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T93","span":{"begin":380,"end":382},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T94","span":{"begin":380,"end":382},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"}],"text":"The recently developed SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are specific to the S1 subunit of S protein, particularly the RBD [5,89–10]. Therefore, the 2019-nCoV S-RBD is anticipated to be a key target for developing 2019-nCoV neutralizing mAbs. The neutralizing mAbs targeting non-RBD regions, including NTD and S2 of SARS-CoV and/or MERS-CoV S could also be identified [5,8,11,12], although their neutralizing potency is generally lower than that of RBD-specific mAbs."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T50","span":{"begin":163,"end":170},"obj":"Chemical"},{"id":"T51","span":{"begin":380,"end":382},"obj":"Chemical"}],"attributes":[{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"}],"text":"The recently developed SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are specific to the S1 subunit of S protein, particularly the RBD [5,89–10]. Therefore, the 2019-nCoV S-RBD is anticipated to be a key target for developing 2019-nCoV neutralizing mAbs. The neutralizing mAbs targeting non-RBD regions, including NTD and S2 of SARS-CoV and/or MERS-CoV S could also be identified [5,8,11,12], although their neutralizing potency is generally lower than that of RBD-specific mAbs."}

{"project":"LitCovid-sentences","denotations":[{"id":"T37","span":{"begin":0,"end":203},"obj":"Sentence"},{"id":"T38","span":{"begin":204,"end":312},"obj":"Sentence"},{"id":"T39","span":{"begin":313,"end":537},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The recently developed SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are specific to the S1 subunit of S protein, particularly the RBD [5,89–10]. Therefore, the 2019-nCoV S-RBD is anticipated to be a key target for developing 2019-nCoV neutralizing mAbs. The neutralizing mAbs targeting non-RBD regions, including NTD and S2 of SARS-CoV and/or MERS-CoV S could also be identified [5,8,11,12], although their neutralizing potency is generally lower than that of RBD-specific mAbs."}